TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07133425: A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

Sponsor: M.D. Anderson Cancer Center · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 29 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07133425 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07133425 Rescue Dossier →